Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background Seroma formation is a common problem after mastectomy. The incidence various between 30% to 92%. It is often an ongoing problem after removal of the suction drain, and repeated skin puncture is necessary to remove the seroma. In addition to many ambulatory visits this also leads to an increased risk of infection, and the adjuvant treatment can be delayed for several weeks
Different procedures have been tried to avoid seroma formation. Among these are for ex. : immobilisation of the arm and shoulder after mastectomy, different drain regimens, closing of the dead space of the cavity, different chemical substances as thrombin, tranexamacid and fibrin. Non of these results has been successful.
Seroma formation is most likely the result of the inflammatory response due to wound healing. In the seroma fluid several factors have been detected that support this assumption. These factors are: high levels of IgG, leucocytes, granulocytes, proteinases, proteinases inhibitors, different kinds of cytokines ( tPA, uPA,, uPAR, PAI-1, PAI-2, IL-6 og IL-1).
On the basis of this, an inhibition of the inflammatory response might result in a decrease of seroma formation, and perhaps improve quality of life after mastectomy.
Steroids inhibit the inflammatory response for example by inhibition of the cytokine function. It has been shown that a high single dose of steroid infusion (30mg/kg solu-medrol) inhibits the normal IL 6 response after colon resection. Newer studies have shown that even at a lower dose the inflammatory response is inhibited. In several studies of head and neck surgery the oedema in surgical area is reduced after a single dose of 125 mg solumedrol. It is precisely this effect of reduced fluid formation we want to obtain in our study. We have therefore chosen to use a single dose of 125 mg of solumedrol in this study. Even at the largest single dose of glucocorticoids there have not been seen any increasing in surgical complications.
The aim of the study: To find out whether single dose of glucocorticoid can reduce the seroma formation after mastectomy
Study design : A randomised pilot study, with 2 x 20 patients. 125 mg solumedrol is given 1,5 hours before surgery in 20 patients, and the other 20 patients are the control group
Inclusion criteria: Women with primary breast cancer, undergoing a mastectomy with either sentinel node biopsy or complete axillary dissection.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Neoplasms Mastectomy |
Drug: Solu-medrol 125 mg |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma |
- seroma formation
| Estimated Enrollment: | 40 |
| Study Start Date: | December 2005 |
| Estimated Study Completion Date: | December 2007 |
Background Seroma formation is a common problem after mastectomy. The incidence various between 30% to 92%. It is often an ongoing problem after removal of the suction drain, and repeated skin puncture is necessary to remove the seroma. In addition to many ambulatory visits this also leads to an increased risk of infection, and the adjuvant treatment can be delayed for several weeks
Different procedures have been tried to avoid seroma formation. Among these are for ex. : immobilisation of the arm and shoulder after mastectomy, different drain regimens, closing of the dead space of the cavity, different chemical substances as thrombin, tranexamacid and fibrin. Non of these results has been successful.
Seroma formation is most likely the result of the inflammatory response due to wound healing. In the seroma fluid several factors have been detected that support this assumption. These factors are: high levels of IgG, leucocytes, granulocytes, proteinases, proteinases inhibitors, different kinds of cytokines ( tPA, uPA,, uPAR, PAI-1, PAI-2, IL-6 og IL-1).
On the basis of this, an inhibition of the inflammatory response might result in a decrease of seroma formation, and perhaps improve quality of life after mastectomy.
Steroids inhibit the inflammatory response for example by inhibition of the cytokine function. It has been shown that a high single dose of steroid infusion (30mg/kg solu-medrol) inhibits the normal IL 6 response after colon resection. Newer studies have shown that even at a lower dose the inflammatory response is inhibited. In several studies of head and neck surgery the oedema in surgical area is reduced after a single dose of 125 mg solumedrol. It is precisely this effect of reduced fluid formation we want to obtain in our study. We have therefore chosen to use a single dose of 125 mg of solumedrol in this study. Even at the largest single dose of glucocorticoids there have not been seen any increasing in surgical complications.
The aim of the study: To find out whether single dose of glucocorticoid can reduce the seroma formation after mastectomy
Study design : A randomised pilot study, with 2 x 20 patients. 125 mg solumedrol is given 1,5 hours before surgery in 20 patients, and the other 20 patients are the control group
Inclusion criteria: Women with primary breast cancer, undergoing a mastectomy with either sentinel node biopsy or complete axillary dissection.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women with primary breast cancer, planned for a mastectomy with and axillary dissection.
- Age over 18 years
- signed informed consent.
Exclusion Criteria:
- Men
- Treatment with glucocorticoids within the last month before surgery, including inhalation products
- Pregnant.
- Not able to speak danish
- Severe heart disease
- Treatment with carbamazepine, phenytoin, phenobarbital, rifampicin, salicylates and ciclosporin
- Uræmia
- Diabetes
- Other medical conditions, evaluated by the investigator, that make tke patient unfit for participation
- previous psychosis
Contacts and Locations| Denmark | |
| Herlev Hospital, breast surgery | Recruiting |
| Herlev, Copenhagen, Denmark, 2730 | |
| Contact: Mette Okholm +4544884488 ext 87406 meok@herlevhosp.kbhamt.dk | |
| Principal Investigator: mette Okholm | |
| Principal Investigator: | Christen Axelsson |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00307606 History of Changes |
| Other Study ID Numbers: | seromprotocol |
| Study First Received: | March 27, 2006 |
| Last Updated: | September 5, 2007 |
| Health Authority: | Denmark: The Regional Committee on Biomedical Research Ethics Denmark: Danish Medicines Agency Denmark: Danish Dataprotection Agency |
Keywords provided by Herlev Hospital:
|
Mastectomy Seroma Breast cancer Glucocorticoid |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms Seroma Neoplasms by Site Breast Diseases Skin Diseases Inflammation Pathologic Processes Methylprednisolone acetate Prednisolone acetate Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone Prednisolone hemisuccinate Prednisolone phosphate |
Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal |
ClinicalTrials.gov processed this record on June 18, 2013